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David R. Holmes, JR, MD,y Michael J. Mack, MDzI n 1965, Gordon Moore, then Fairchild Semicon-ductor’s director of Research and Development,attempted to predict the continued development
of integrated electronics by a principle now known as
“Moore’s law” in the semiconductor industry andmod-
ern computing. In essence, it describes the fact that the
number of transistors on an integrated circuit has been
doubling approximately every 2 years, making devices
more efﬁcient, more powerful, and better able to do
“complex procedures” than ever. An analogous princi-
ple could be construed to exist in the ﬁeld of interven-
tional cardiology, where every 18 months or so a
new generation of devices is introduced into the
marketplace that are designed to improve the out-
comes of complex procedures in increasingly complex
patients. Interventional cardiology has ﬁrst-generation
drug-eluting stents (DES), which are not even manufac-
tured anymore, and subsequent second-, third-, and
now even fourth-generation DES. The question remains,
despite the fact that Moore’s law as a driving principle
in integrated electronics has resulted in dramatic im-
provements in complex procedures, whether new gener-
ations of DES translate to similar improvements in
complex procedures in interventional cardiology.SEE PAGE 1657The patient-level pooled analysis by Piccolo et al.
(1), in this issue of JACC: Cardiovascular Interventions,
of 6,081 patients comparing the effectiveness and
safety of new-generation versus early generation DES
is focused on evaluating technological improvements.
It is important for several reasons. Despite the fact
that trials and randomized studies of percutaneous
coronary intervention (PCI) with DES versus coronary
artery bypass graft (CABG) for the treatment of*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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that composite endpoints of death, stroke, and target
lesion revascularization are still better with coronary
bypass graft surgery (2–8), the iterative science/art of
interventional cardiology continues to work on tech-
nological improvements that could potentially narrow
the gap and allow PCI to be considered as equivalent
in the setting of complex multivessel disease (9).
Because randomized trials of DES versus CABG were
typically carried out with ﬁrst-generation stents, as
technology has improved, so might the longer-term
efﬁcacy and safety results. In the Piccolo et al. (1)
analysis, the individual patient-level data from 4
recent randomized clinical trials conducted between
2004 and 2013 with the exclusive use of DES (SIRTAX
[Sirolimus-Eluting and Paclitaxel-Eluting Stent for
Coronary Revascularization], LEADERS [Limus Eluted
From a Durable Versus Erodible Stent Coating],
RESOLUTE All Comers [Randomized Comparison of
a Zotarolimus-Eluting Stent With an Everolimus-
Eluting Stent for Percutaneous Coronary Interven-
tion], and BIOSCIENCE [Ultrathin Strut Biodegradable
Polymer Sirolimus-Eluting Stent Versus Durable
Polymer Everolimus-Eluting Stent for Percutaneous
Coronary Revascularization]) were analyzed. All of
the trials included both stable and acute coronary
syndrome patients; the ﬁrst-generation DES stents
used were the ﬁrst 2 DES approved in the United
States (sirolimus: Cypher or Cypher Select, Cordis,
Miami Lakes, Florida; and paclitaxel: Taxus, Boston
Scientiﬁc, Natick, Massachusetts). The newer gener-
ation stents include everolimus, zotarolimus, and
biodegradable polymers, biolimus, and sirolimus. The
primary device-oriented clinical endpoint was the
composite of cardiac death, nonfatal myocardial
infarction, or ischemia-driven target lesion revascu-
larization (TLR). Effectiveness and safety endpoints
were TLR and deﬁnite stent thrombosis.
In the overall population, Moore’s law of im-
proved performance by technologic improvements
was validated. At 2 years, the primary endpoint in an
adjusted analysis was signiﬁcantly improved with
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1668new-generation DES (hazard ratio [HR]: 0.75, 95%
conﬁdence interval [CI]: 0.63 to 0.89, p ¼ 0.001). Si-
milarly, cardiac death (HR: 0.60, 95% CI: 0.42 to 0.85,
p ¼ 0.004), clinically indicated TLR (HR: 0.56, 95% CI:
0.44 to 0.70, p<0.001), target vessel revascularization
(HR: 0.61, 95% CI: 0.49 to 0.75, p < 0.001), and deﬁnite
stent thrombosis (HR: 0.40, 95% CI: 0.25 to 0.65,
p < 0.001) were all signiﬁcantly improved (see
Figures 3A, 3B, 4A, and 5 in Piccolo et al. [1]). Accord-
ingly, the investigators conclude that “new generation
DES improved clinical outcomes comparedwith earlier
generation DES.”
The rest of the story is different and deals with
apples and oranges, although both are fruits, are quite
different. This relates to a second primary focus of the
study—to compare the outcome of PCI depending on
the complexity of coronary artery disease. Unfortu-
nately, apples and oranges are mixed here. The in-
vestigators relate their analysis to the pivotal SYNTAX
(Synergy Between Percutaneous Coronary Interven-
tion With Taxus and Cardiac Surgery) trial and the
SYNTAX score based upon the complexity of coronary
artery disease. A crucial analysis in the original
SYNTAX publication was the use of tertiles of
complexity with a low score #22, an intermediate
score of 23 to 32, and a high score $33 (2).
In the ﬁnal 5-year analysis of the SYNTAX trial,
there were important differences in outcomes based
upon the tertile SYNTAX score (10). In patients in the
lowest tertile (score 0 to 22), there was no signiﬁcant
difference in outcome between CABG and PCI; there
was only a trend in difference in revascularization
(p ¼ 0.056). This occurred even despite the use of
ﬁrst-generation DES. There was, however, a signiﬁ-
cant difference between CABG and PCI in patients in
the middle and upper tertiles with CABG being
signiﬁcantly better. Unfortunately, the current paper
by Piccolo et al. (1) confuses us in some ways because
it groups patients apparently by design into only low
or high complexity using the median score #11 or $11.
In this analysis, in the “high CAD complexity group”
some patients may have been considered in the
lowest tertile in the SYNTAX trial making any po-
tential comparisons difﬁcult. Although according to
the statistical analysis plan, it appears that this
grouping into “low and high complexity” was by
design, it would have been easier to interpret the
ﬁndings if the SYNTAX tertile grouping had been
used. It would have been particularly valuable to
know the performance of a new-generation DES in
the highest risk tertile of the patients using the
cutoff of $33. In this most complex group of patients,
CABG has been found to be substantially superior.
Given that this is a large group of multivessel diseasepatients, attempts at expanding PCI with new tech-
nology should be at least assessed in this group.
Irrespective of the issues of apples (SYNTAX
score#11 vs.$11) and oranges (STYNTAX score#22, 22
to 32 and $33), this study adds important information
to the published data. Patients with a higher SYNTAX
score >11 receiving a new-generation DES had signiﬁ-
cantly improved primary major adverse cardiac event
rates (HR: 0.68, 95% CI: 0.54 to 0.85, p ¼ 0.001)
compared with the patients with less complex disease
in whom the difference was not signiﬁcant. Similarly,
cardiac death was signiﬁcantly less (p < 0.001) in
patients with SYNTAX score >11 receiving a new-
generation DES but was not signiﬁcantly different in
patients with less complex disease. Other endpoints
included clinically indicated TLR, target vessel revas-
cularization, and stent thrombosis were all signiﬁ-
cantly less in the “high complexity” with newer-
generation DES but were not different in patients
with less complex disease. The investigators could
have concluded from this part of the paper that “new
generation DES improved clinical outcomes compared
with early generation DES with clinically signiﬁcant
greater safety and effectiveness only in patients with
SYNTAX score >11.”
Where then do we, as individual cardiologists and
cardiovascular surgeons, stand with this new robust
analysis of data from 4 recent large trials? We can say:
1. Moore’s law in integrated electronics, where
important advances occur with each new genera-
tion, is also true in interventional cardiology, and
new DES stents perform better in terms of safety
and effectiveness than older versions do.
2. In patients with clinical moderate disease, the
impact of these new stents is more important as
the disease becomes more complex.
3. In patients with the most complex disease (SYNTAX
score >33) we do not know the impact of these new
stents, and for now the results of the randomized
clinical trials on CABG versus PCI in these
most complex patients remains untested. In
the meantime, we can look forward to the results
of the completely enrolled Excel Clinical Trial
NCT01205776 of everolimus eluting stents in
patients with left main disease and a SYNTAX
score <33 for validation of the progress that this
meta-analysis appears to demonstrate.
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